Blood Reviews
短名 | Blood Rev. |
Journal Impact | 6.74 |
国际分区 | HEMATOLOGY(Q1) |
期刊索引 | SCI Q1中科院 2 区 |
ISSN | 0268-960X, 1532-1681 |
h-index | 112 |
国内分区 | 医学(2区)医学血液学(2区) |
这本受人尊敬的国际期刊《血液评论》是一个重要的信息资源,汇集了临床实践评估和公认专家的研究。来自领先研究人员和从业者的特别委托文章保证了对血液学所有子专业的真正全球覆盖。 BLOOD REVIEWS 发表评论文章,涵盖临床和实验室血液学实践和研究的范围。尽管大多数评论都是被邀请的,但编辑们欢迎潜在作者的建议。他们应该首先写一份预期审查的简短大纲,并将其发送给 TREVOR BAGLIN 博士或 JACOB M ROWE 博士。
期刊主页投稿网址涉及主题 | 医学生物内科学免疫学遗传学病理化学外科生物化学心理学精神科细胞生物学疾病重症监护医学癌症研究 |
出版信息 | 出版商: Churchill Livingstone,出版周期: Bimonthly,期刊类型: journal |
基本数据 | 创刊年份: 1987,原创研究文献占比: 0.00%,自引率:1.40%, Gold OA占比: 27.59% |
平均审稿周期 | 网友分享经验:约稿?周期不定 |
平均录用比例 | 网友分享经验:较难 |
期刊引文格式
这些示例是对学术期刊文章的引用,以及它们应该如何出现在您的参考文献中。
并非所有期刊都按卷和期组织其已发表的文章,因此这些字段是可选的。有些电子期刊不提供页面范围,而是列出文章标识符。在这种情况下,使用文章标识符而不是页面范围是安全的。
只有1位作者的期刊
有2位作者的期刊
有3位作者的期刊
有5位以上作者的期刊
书籍引用格式
以下是创作和编辑的书籍的参考文献的示例。
学位论文引用格式
网页引用格式
这些示例是对网页的引用,以及它们应该如何出现在您的参考文献中。
专利引用格式
最新文章
Dismantling relapsed/refractory mantle cell lymphoma
2024-9-1
Editorial Board
2024-9-1
Clinical applications of circulating tumor DNA in hematological malignancies: From past to the future
2024-9-1
Advancing CAR T-cell therapies: Preclinical insights and clinical translation for hematological malignancies
2024-9-1
Tailoring oral anticoagulant treatment in the era of multi-drug therapies for PAH and CTEPH
2024-9-1
Corrigendum to “Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?”[BLOOD REVIEWS, 9 August 2024, https://doi.org/10.1016/j.blre.2024.101226]
2024-9-1
Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?
2024-8-1
Autologous stem cell transplantation in AL amyloidosis: Muddy waters
2024-8-1
Absolute and functional iron deficiency: Biomarkers, impact on immune system, and therapy
2024-8-1
Addressing the surge of infections by multidrug-resistant Enterobacterales in hematopoietic cell transplantation
2024-8-1
Ven the dose matters: Venetoclax dosing in the frontline treatment of AML
2024-8-1
Longitudinal clinical manifestations of Fanconi anemia: A systematized review
2024-8-1
Editorial Board
2024-7-1
De-novo immune-mediated thrombotic thrombocytopenic purpura following surgical and non-surgical procedures: A systematic review
2024-7-1
Current challenges in conditioning regimens for MDS transplantation
2024-7-1
Breaking down frailty: Assessing vulnerability in acute myeloid leukemia
2024-7-1
Factor B inhibitor iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria
2024-7-1
Cancer cytogenetics in a genomics world: Wedding the old with the new
2024-7-1
Thrombotic events associated with immune checkpoint inhibitors and novel antithrombotic strategies to mitigate bleeding risk
2024-6-7
Gut microbiome composition and dysbiosis in immune thrombocytopenia: A review of literature
2024-6-6
Endothelial injury and dysfunction with emerging immunotherapies in multiple myeloma, the impact of COVID-19, and endothelial protection with a focus on the evolving role of defibrotide
2024-6-3
Immune thrombocytopenia: Pathophysiology and impacts of Romiplostim treatment
2024-6-1
The acute pain crisis in sickle cell disease: What can be done to improve outcomes?
2024-5-1
BCL-2 inhibition in haematological malignancies: Clinical application and complications
2024-5-1
Revolutionising healing: Gene Editing's breakthrough against sickle cell disease
2024-5-1
When anticoagulation management in atrial fibrillation becomes difficult: Focus on chronic kidney disease, coagulation disorders, and cancer
2024-5-1
Update: The molecular spectrum of virus-associated high-grade B-cell non-Hodgkin lymphomas
2024-5-1
Editorial Board
2024-5-1
Disparity in hematological malignancies: From patients to health care professionals
2024-5-1
Current status and prospect of anti-amyloid fibril therapy in AL amyloidosis
2024-4-1
Advances in the treatment of Philadelphia chromosome negative acute lymphoblastic leukemia
2024-4-1
Chronic myeloid leukaemia: Biology and therapy
2024-3-27
From microscope to micropixels: A rapid review of artificial intelligence for the peripheral blood film
2024-3-1
Heartbreaker: Detection and prevention of cardiotoxicity in hematological malignancies
2024-3-1
Platelet factor 4(PF4) and its multiple roles in diseases
2024-3-1
Idiopathic multicentric Castleman disease: An update in diagnosis and treatment advances
2024-3-1
Chromosomal defects in multiple myeloma
2024-3-1
Optimizing high dose melphalan
2024-3-1
Immune deficiency/dysregulation -associated lymphoproliferative disorders. Revised classification and management
2024-3-1
Corrigendum to “Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme” [Blood Rev. 2023 Sep:61:101103]
2024-3-1
Nothing short of a revolution: Novel extended half-life factor VIII replacement products and non-replacement agents reshape the treatment landscape in hemophilia A
2024-3-1
Richter's transformation: Transforming the clinical landscape
2024-3-1
Editorial Board
2024-3-1
Paroxysmal nocturnal hemoglobinuria: Review of the patient experience and treatment landscape
2024-3-1
Iron deficiency anemia among women: An issue of health equity
2024-3-1
Practical considerations in clinical application of WHO 5th and ICC classification schemes for acute myeloid leukemia
2024-3-1
Contemporary tools for evaluation of hemostasis in neonates. Where are we and where are we headed?
2024-3-1
Down syndrome and leukemia: An insight into the disease biology and current treatment options
2024-3-1
Unraveling germline predisposition in hematological neoplasms: Navigating complexity in the genomic era
2024-3-1
Targeting hematologic malignancies by inhibiting E-selectin: A sweet spot for AML therapy?
2024-2-1
帮你贴心管理全部的文献
研飞ivySCI,高效的论文管理
投稿经验分享
分享我的经验,帮你走得更远